Amgens monthly maridebart cafraglutide and Novo Nordisks fixed-dose CagriSema combination target superior efficacy without added injection frequency, signaling competitive dimensions will increasingly pivot on dosing simplicity and multi-pathway synergy
However, they should not be used together or with any other GLP-1 or GIP receptor agonists
Common side effects (mild nausea, occasional GI upset) are most pronounced during dose increases and typically improve
doi: 10.1007/s11095-010-0330-4
Starting Dose and Gradual Dose Adjustment Management is typically initiated at a lower dose and gradually increased to minimise gastrointestinal side effects and improve tolerability, as directed by the doctor
As far as using them together, the recent findings are promising, but theyre still very early, says Faubion